HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

der to reduce the incidence and severity of infusion-related adverse events. Patients also received prophylactic anti-infective treatment to reduce the risk of opportunistic infections. The primary endpoint for this trial was overall response rate (complete and partial response), and the study objective was to demonstrate a major response rate of at least 20 percent. Response rate was assessed by an independent review panel in accordance with the National Cancer Institute's guidelines for the diagnosis and treatment of CLL.

Of 93 evaluable patients, 31 demonstrated an objective response to treatment, for an overall response rate of 33%. Two of these responses were complete (2%) and 29 were partial responses (31%). Another 55 (59%) patients had disease stabilization. Median survival time has not yet been reached at about 10 months after the last patient was enrolled.

The safety profile of CAMPATH was consistent with that seen in previous studies and was judged by the investigators to be acceptable in this group of endstage CLL patients.

Adverse effects associated with CAMPATH in this study of 93 patients were mostly mild to moderate infusion-related symptoms. Severe (grade 3 and 4) infusion-related symptoms included: fever (13%), rigors (11%), dyspnea (6%), and hypotension (1%). During the study patients developed severe (grade 3 and 4) thrombocytopenia (low platelet count, 51%) or neutropenia (low white blood cell count, 61%) that usually improved within two months post-therapy. Some patients entering the study with severe (grade 3 and 4) thrombocytopenia and neutropenia improved to grade 2 or better within two months post-therapy: thrombocytopenia -- 7 of 19 (37%) patients improved,neutropenia -- 11 of 17 (65%) patients improved.

No unexpected serious adverse events were reported. The incidence of serious infections was reported to be 20% on this trial. It should be noted that infection is a common complication and cause of death
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2019)... ... March 20, 2019 , ... ... of customized NextGen® Practice Management (PM) and Electronic Health Record (EHR) solutions, received ... Service . This year marks the fifth consecutive year TSI Healthcare has been ...
(Date:3/20/2019)... ... March 20, 2019 , ... EBSCO ... decision aids, has announced the certification of two decision aids by the ... and Down Syndrome Screening Test: Yes or No? Currently, Washington is the only ...
(Date:3/20/2019)... (PRWEB) , ... March 20, 2019 , ... ... introduce its newly designed website as an improved online resource for ABFM Diplomates. ... informative and easy to navigate. , The new website features a responsive design, ...
(Date:3/20/2019)... ... March 20, 2019 , ... Natreon has been granted ... trivalent chromium chloride combined with extracts of amla and shilajit, that has a ... along with 7 clinical studies on Crominex®3+, establish this ingredient as the ideal ...
(Date:3/20/2019)... ... March 20, 2019 , ... James Koelbl, DDS, ... (KCU) as vice provost for oral health initiatives. Koelbl will assist in KCU’s ... Dental Medicine on the university’s Joplin, Missouri, campus. The proposed program will serve ...
Breaking Medicine News(10 mins):
(Date:3/20/2019)... ... March 20, 2019 , ... ... announced release of ground-breaking mechanisms specifically designed to help healthcare and clinical ... local and international regulations and continue to lower costs by improving efficiency, ...
(Date:3/20/2019)... ... March 20, 2019 , ... Using data from computed tomography ... respond to chemotherapy, according to a new study published in the journal ... advanced-stage non–small cell lung cancer (NSCLC). However, only about one in four patients ...
(Date:3/20/2019)... ... 2019 , ... According to Prevent Blindness, the nation’s oldest eye ... such as cataract, glaucoma and age-related macular degeneration. Women have a higher prevalence ... menopause. , Prevent Blindness has designated April as Women’s Eye Health and Safety Month ...
Breaking Medicine Technology:
Cached News: